Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Pelikan Technologies funds electronic lancet launch: Electronic lancet developer raises $69 million in a "Series F" private placement led by Clarus Ventures, Pelikan announces Dec. 6. The privately held firm also has received approval for a $20 million venture capital loan from General Electric Capital and Oxford Finance. A portion of the $89 million in total funds raised will be used to support a 2008 U.S. launch of the 510(k)-cleared Pelikan Sun electronic lancing device, the firm says. The fully automated device, which debuted in Australia in October and in Europe in November, is designed to reduce pain associated with blood sample collection and enhance ease-of-use. Palo Alto, Calif.-based Pelikan Technologies also will use a portion of the proceeds for continued development of a system integrating Pelikan Sun with a blood glucose monitor. A 2008 debut of the latter system also is anticipated by the company. UBS Investment Bank was the sole placement agent for Pelikan's private placement
You may also be interested in...
Bioabsorbable Stents Raise New Concerns For Investigators And Regulators
The next big thing in drug-eluting stents might be a simple disappearing act
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.